The Collaborative Clinical Trials Division at UC San Diego has been selected to lead and administer a $ 28 million international seven-year grant for HIV / AIDS clinical trials.
The National Institutes of Health, along with other American, South African and Indian research hospitals, have selected UCSD as part of their seven-year renewal of HIV / AIDS funding. Every seven years, the NIH competitively renews funding for its US and international networks for clinical HIV trials.
During the current application process, the University of San Diego Anti-Virus Research Center, University of Colorado Hospital, Houston AIDS Research Team, and Durban International Clinical Research Sites were selected to collaborate on research priorities for the NIH / National Institute of Allergy and Infectious Diseases to work network for clinical trials of HIV / AIDS adult therapeutics.
The Chennai Antiviral Research and Treatment Center, the University of Southern California, and the University of Miami were also selected to join the UCSD and serve as qualified reserve or protocol-specific sites needed for future clinical trials.
« UC San Diego has shaped HIV / AIDS research and treatment through innovative research since the therapeutic clinical trial networks for adults and children were established in 1986, » said lead researcher Dr. . Constance A. . Benson, director of the UCSD Antiviral Research Center.
« Together, the seven clinical research sites selected by the NIH for the Network for Therapeutic HIV Clinical Trials bring together a wealth of scientific expertise, experience and the high quality performance required to conduct complex clinical trials, » she said.
Around 38 million people worldwide live with HIV / AIDS, including 1. 7 million people will contract HIV in 2019 alone. In the United States 1. 2 million people are living with the virus.
The clinical trials division, led by UCSD, serves multiple regions in the United States prone to chronic and emerging HIV infections, as well as global regions affected by both HIV and tuberculosis.
The division will investigate therapeutic strategies aimed at curing HIV, including assessing virus persistence, research into antibodies for treatment and prevention, and studying the treatment of inflammation and its effects on HIV comorbidities.
In addition, researchers will investigate new drugs, including long-acting drug formulations for HIV treatment and prevention, HIV-related co-infections and comorbidities – including metabolic and end organ complications and a cure for hepatitis B, as well as the treatment and prevention of Tuberculosis, including TB-preventive vaccines, in people co-infected with mono- and HIV.
« We are honored to lead a talented pool of researchers to work together to advance research that will clinically benefit people with HIV, » said Benson.
HIV / AIDS, HIV, Clinical Study, Clinical Research, NIH, National Institutes of Health, University of California, San Diego, Network for HIV Prevention Studies, Management of HIV / AIDS
World News – UK – UC San Diego selected to lead HIV / AIDS international clinical trial
. Related Title :
– UC San Diego as Head Selected International Clinical HIV / AIDS Study
– UC San Diego has chosen to conduct an International Grant of 28 million. USD for HIV / AIDS Clinical Trials
– NIH Announces Restructured Networks for HIV Clinical Trials
– Network for HIV Prevention Studies with US Institutes for Health Financing Awarded for Continuing Research Agenda
– NIH Re-Funds ACTG for the next seven years
Donnez votre avis et abonnez-vous pour plus d’infos
Vidéo du jour: